Background: Alpha-blockers have historically been sidelined in cardiovascular disease management due to concerns regarding neurohormonal activation and heart failure (HF) exacerbation, primarily stemming from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). However, recent epidemiological data, clinical trial outcomes, and fundamental pharmacodynamic principles suggest that their clinical utility is highly context-dependent, prompting a re-evaluation of alpha-blockers in various cardiovascular settings. The aim of this review is to evaluate recent evidence concerning the cardiovascular safety and emerging applications of alpha-blockers. Recent large-scale observational studies and meta-analyses demonstrate that alpha-blockers do not increase hospital readmission rates or mortality among patients with established HF; in fact, they may be associated with improved survival and exercise tolerance. Conversely, epidemiological data on their initiation for benign prostatic hyperplasia (BPH) in patients without prior cardiovascular disease highlight subtle but persistent long-term ischemic risks. Furthermore, this review explores emerging applications in interventional cardiology, notably the use of periprocedural phentolamine to prevent contrast-associated acute kidney injury (CA-AKI). By detailing these evolving roles, including the management of resistant hypertension and cocaine-induced acute coronary syndromes, this review emphasizes a critical transition from broad historical contraindications toward tailored, patient-specific management. The resurgence of alpha-blockers highlights their potential utility beyond hypertension and BPH, particularly in cardioprotection and renal preservation